Through its technology innovation in the field of biomedical polymers, PolyTherics has established a strong position in adapting proteins for therapeutic application. The company's most advanced programmes exploit the inert, non-toxic polymer PEG (polyethylene glycol) to stabilise and increase the solubility of proteins and extend their half-life in vivo.

PEG has long been approved for oral, intradermal and parenteral application in man. PEGylated drugs have been developed for a wide range of indications, including peptide/protein anti-cancer agents, antibody fragments, cytokines, enzyme replacement and blood component substitutes. While products PEGylated by current methodologies have enjoyed commercial success, they are frequently compromised by reduced protein bioactivity, chemical heterogeneity and complexicity and cost of manufacturing.